Linagliptin

Hormones

Rabin Medical CenterSmall moleculePhase 3Dormant

CCC

55/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 40/ 100
Competitive Position: 95/ 100

Competitive context

5 Active assets in the Hormones cohort.

Asset / Sponsor	Phase	Rating
Abiraterone Acetate Eli Lilly and Company	Phase 3	B
Abemaciclib Eli Lilly and Company	Phase 3	B
PREDNISONE TABLETS Eli Lilly and Company	Phase 3	B
CHLOROPTIC-P S.O.P. COMPONENT PREDNISOLONE Eli Lilly and Company	Phase 3	B
Amylin Danish Headache Center	N/A	D

Same molecule, other indications

Linagliptin is also rated in:

type 2 diabetes mellitusDormant

B

Indicative ·

62 / 100

polycystic ovary syndromeDormant

B

Indicative ·

58 / 100

metabolic dysfunction-associated steatotic liver diseaseDormant

B

Indicative ·

58 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.